{
    "clinical_study": {
        "@rank": "111067", 
        "acronym": "A-MANECE", 
        "arm_group": [
            {
                "arm_group_label": "MINOCYCLINE 8 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Duration of treatment: 8 weeks\nPatients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.\nPatients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.\nPatients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
            }, 
            {
                "arm_group_label": "PLACEBO 8 weeks", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Pill manufactured to mimic Minocycline 50 mg capsule"
            }, 
            {
                "arm_group_label": "MINOCYCLINE 16 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Duration of treatment: 16 weeks\nPatients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.\nPatients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.\nPatients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
            }
        ], 
        "brief_summary": {
            "textblock": "RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF\n      MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY)"
        }, 
        "brief_title": "Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Angelman Syndrome", 
        "condition_browse": {
            "mesh_term": "Angelman Syndrome"
        }, 
        "detailed_description": {
            "textblock": "STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female between 6 and 30 years old.\n\n          -  Clinical diagnosis of Angelman Syndrome and molecular confirmation of diagnosis.\n\n          -  The participant has an acceptable guardian can give consent on behalf of the\n             participant.\n\n        Exclusion Criteria:\n\n          -  Patients with hypersensitivity to tetracyclines.\n\n          -  Patients with impaired hepatic or renal function and in those with mainly drug\n             allergy history.\n\n          -  Any other condition that in the opinion of the investigator is considered clinically\n             relevant and that administration of minocycline contraindicated"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02056665", 
            "org_study_id": "A-MANECE"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MINOCYCLINE 8 weeks", 
                    "PLACEBO 8 weeks", 
                    "MINOCYCLINE 16 weeks"
                ], 
                "intervention_name": "MINOCYCLINE", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Commercial name: Aknemin 50", 
                    "Active substance:  MINOCYCLINE", 
                    "Administration routes:  Oral use"
                ]
            }, 
            {
                "arm_group_label": [
                    "MINOCYCLINE 8 weeks", 
                    "PLACEBO 8 weeks"
                ], 
                "description": "Pill manufactured to mimic Minocycline 50 mg capsule", 
                "intervention_name": "PLACEBO (for Minocycline)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Commercial name: NA", 
                    "Non Active substance:", 
                    "Administration routes: Oral use"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Minocycline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Angelman Syndrome", 
            "EFFICACY", 
            "SAFETY", 
            "MINOCYCLINE", 
            "Pediatrics population", 
            "Rare diseases"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "contact": {
                "email": "mariabelen.ruiz@salud.madrid.org", 
                "last_name": "Belen Ruiz-Antoran", 
                "phone": "34911917479"
            }, 
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28222"
                }, 
                "name": "Puerta de Hierro University Hospital"
            }, 
            "investigator": {
                "last_name": "Belen Ruiz-Antor\u00e1n", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome", 
        "overall_contact": {
            "last_name": "Belen Ruiz-Antoran", 
            "phone": "34911917479"
        }, 
        "overall_official": {
            "affiliation": "Clinical Pharmacology. Puerta de Hierro University Hospital", 
            "last_name": "Belen Ruiz-Antor\u00e1n", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Increased on the equivalent age of development, obtained through Development Scale R Merrill-Palmer (MP-R)", 
            "measure": "Increased on the equivalent age of development", 
            "safety_issue": "No", 
            "time_frame": "8, 16 and 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02056665"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Puerta de Hierro University Hospital", 
            "investigator_full_name": "BELEN RUIZ-ANTORAN", 
            "investigator_title": "DR", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Improved specific cognitive, language and communication, motor development, social-emotional and adaptive behavior obtained through Development Scale R Merrill-Palmer (MP-R)", 
                "measure": "Improved specific cognitive, language and communication, motor development, social-emotional and adaptive behavior", 
                "safety_issue": "No", 
                "time_frame": "8, 16 and 24 weeks"
            }, 
            {
                "description": "Improvement of EEG. Measure based on changes in the background activity, type, number and duration of crises, widespread tendency to crises, paroxysmal abnormalities recorded types and the overall evaluation of clinical neurophysiologist", 
                "measure": "Improvement of EEG.", 
                "safety_issue": "No", 
                "time_frame": "8, 16 and 24 weeks"
            }, 
            {
                "description": "a) Physical Examination b) Vital signs c) Laboratory Tests d) Adverse effects (AEs) list for treatment, laboratory values, values outside the reference range and descriptive statistics.", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "8, 16 and 24 weeks"
            }, 
            {
                "description": "Improvement of CGI. . Measure based on changes in the Clinical Global Impression through the perception of parents or guardians, you neurologists and therapist", 
                "measure": "Clinical Global impression (CGI)", 
                "safety_issue": "No", 
                "time_frame": "8, 16 and 24 weeks"
            }
        ], 
        "source": "Puerta de Hierro University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Puerta de Hierro University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}